The German biotech is accelerating its transformation from pandemic-era vaccine giant to oncology-focused drug developer, with two parallel tracks now firmly in view. On one side, management is quietly exploring the sale of three German manufacturing sites and preparing to offload its Berlin peptide subsidiary. On the other, a promising antibody-drug conjugate for metastatic prostate cancer has pushed the stock above a key technical level, signaling that investors are increasingly betting on the pipeline rather than the past.
Plant closures and job cuts take shape
The restructuring plan announced in May is now moving from blueprint to execution. BioNTech has entered confidential negotiations with potential buyers for its sites in Idar-Oberstein, Marburg and Tübingen, which are slated to close by the end of 2027. The Singapore facility will follow in the first quarter of 2027. Up to 1,860 jobs hang in the balance across the German sites alone.
A separate divestiture is underway for JPT Peptide, the Berlin-based subsidiary acquired in 2009. BioNTech aims to sell the unit by the end of 2026, affecting roughly 140 positions. The peptide business has become unprofitable, and the company is already sourcing a new supplier for those components.
ADC candidate BNT324/DB-1311 builds momentum
While the factory news might have weighed on sentiment in a different environment, the stock has been lifted by progress in the oncology pipeline — specifically the anti-B7-H3 antibody-drug conjugate BNT324/DB-1311. At the end of June, BioNTech updated the clinical trial registries for the global Phase 3 registrational study comparing the candidate against standard chemotherapy with docetaxel in patients with metastatic castration-resistant prostate cancer. The first patient was dosed in late May.
This program is emerging as a key pillar of BioNTech’s ambition to run 15 concurrent Phase 3 studies by the end of 2026. The broader pipeline was also highlighted at the ASCO annual meeting in early June with data from the ROSETTA Lung-02 study, but the ADC update appears to have been the catalyst for the stock’s recent gains.
A cash cushion and a buyback underpin the stock
The restructuring is costly, but the balance sheet provides ample room. BioNTech holds around €16.8 billion in cash and securities. That firepower supports a share buyback program of up to $1 billion, which alongside a reaffirmed 2026 revenue forecast of €2.0–2.3 billion has helped stabilize the stock after a volatile first quarter.
Should investors sell immediately? Or is it worth buying BioNTech?
The financial reality of declining COVID vaccine sales is evident in the numbers: first-quarter 2026 revenue came in at €118.1 million, leading to a net loss of €531.9 million. Management nonetheless confirmed its full-year guidance. Annual savings of roughly €500 million from the manufacturing consolidation are expected to eventually improve the bottom line, though the timeline depends on how quickly the plant sales and closures proceed.
Technical picture brightens after a tough 12 months
The stock closed Friday at €84.30, down 1.23% on the day, but that did little to erase the week’s gains. Over the past seven sessions, BioNTech advanced 5.57%, and the monthly return now stands at 10.48%. Year-to-date the shares are up 2.18%, though the 12-month comparison remains negative at -9.84%.
On a technical basis, the recovery has been meaningful. The price has reclaimed the 50-day moving average at €80.01 and now trades 5.36% above it. The next hurdle is the 200-day line at €85.35 — less than 2% away. A sustained break above that level would signal a stronger trend reversal. The RSI of 62.7 points to moderate buying pressure without entering overbought territory.
The stock is still 20% below its 52-week high of €105.80 from January, but it has rebounded 23.34% from the March low of €68.35. The 30-day volatility, at 30.94%, has moderated from the first-quarter peaks.
What’s next: Phase 3 count and second-quarter numbers
Investors will get a fresh look at the pipeline on 4 August, when BioNTech reports second-quarter 2026 results. The update is expected to include details on the 13 active Phase 3 studies and progress on the manufacturing footprint consolidation. With the factory sale talks now underway and a prostate cancer candidate advancing through registrational testing, the company is inching closer to its stated goal of becoming a multiproduct oncology business by 2030.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from July 4 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 4.
BioNTech: Buy or sell? Read more here...
